ACTRN12610000821099已完成2 期
A Phase II, multi-centre, 12-week, randomised, double-blind, placebo controlled, dose ranging study of the efficacy and safety of NatraGuard(trademark) (a bovine whey protein isolate) in postmenopausal women undertaking a combination of aerobic and resistance exercise training programs for the improvement of muscle strength and body composition.
MG Nutritionals - a Division of Murray Goulburn Co-op. Co. Ltd0 个研究点目标入组 160 人开始时间: 2010年9月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 50 Years 至 70 Years（—）
- 性别
- Female
入选标准
- •overweight postmenopausal women currently participating in regular physical activity 2-3 times per week, but not under supervision of a personal trainer
排除标准
- •lactose intolerance or allergy to cow's milk protein, current smoker or excess alcohol consumption, Diabetes, diagnosed osteoporosis or upper/lower extremity fracture in past 3 months, vitamin D deficiency, use of medications that affect bone or muscle metabolism, history of malignancy or elevated cancer markers at screening, elevated blood pressure
研究者
相似试验
进行中（未招募）
不适用
A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled,pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 maleand female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are treatmentnaïve.Type 2 diabetes mellitusMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-004694-97-HUGlaxoSmithKline Research & Development336
进行中（未招募）
不适用
A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidemia.Obesity and mixed dyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityMedDRA version: 9.1Level: LLTClassification code 10058110Term: DyslipidemiaEUCTR2009-010198-19-SEovartis Pharma Services AG450
进行中（未招募）
不适用
A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ908 for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidemia.EUCTR2009-010198-19-GBovartis Pharma Services AG450
进行中（未招募）
不适用
A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidemia.Obesity and mixed dyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityMedDRA version: 9.1Level: LLTClassification code 10058110Term: DyslipidemiaEUCTR2009-010198-19-DKovartis Pharma Services AG450
撤回
2 期
A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis (CCX115393)10017969ulcerative colitisNL-OMON35581GlaxoSmithKline BV20